# DESCRIPTION

- claim benefit of provisional application

## FIELD OF THE INVENTION

- disclose method and compositions for treating solid tumor cancer

## BACKGROUND OF THE INVENTION

- motivate need for new ovarian cancer treatments
- summarize HDAC and IKK inhibitors

## SUMMARY OF THE INVENTION

- summarize method and compositions for treating solid tumor cancer

## DETAILED DESCRIPTION OF THE INVENTION

### I. Methods of Use

- define method for treating solid tumor cancer
- specify HDAC and IKK inhibitors for use
- describe administration methods and schedules
- define therapeutically effective amounts
- specify routes of administration
- provide dosage ranges and examples
- describe methods of use
- specify dosing regimens for HDAC and IKK inhibitors
- explain limitations of HDAC inhibitors in ovarian cancer treatment
- describe combination therapy of HDAC and IKK inhibitors
- outline method for determining susceptibility of cancer to combination therapy
- detail steps for assessing effect of combination therapy on IL-8 production and cell survival

### II. Pharmaceutical Compositions

- define pharmaceutical composition
- describe administration routes
- list pharmaceutical acceptable carriers
- describe solid dosage forms
- describe liquid dosage forms
- discuss delayed release options

### III. Kit

- define kit composition
- describe kit components and usage

## EXAMPLES

- present nonlimiting examples

### Example 1: HDAC Inhibitors Increase IL-8 Expression in Ovarian Cancer Cells

- demonstrate HDAC inhibitors increase IL-8 expression

### Example 2: HDAC Inhibitors Increase IL-8 Expression in Cervical Cancer Cells

- demonstrate HDAC inhibitors increase IL-8 expression

### Example 3: IKK Inhibitors Suppress the HDAC Inhibition-Induced IL-8 Expression in Ovarian Cancer Cells

- show IKK inhibitors suppress HDAC inhibition-induced IL-8 expression

### Example 4: Combination of HDAC Inhibitor and IKK Inhibitor Enhances the HDAC Inhibitor Effectiveness in Reducing Solid Tumor Growth in Vivo

- demonstrate combination therapy enhances HDAC inhibitor effectiveness

